Sector News

Medtronic CEO Ishrak to retire after 8 years at helm

August 29, 2019
Life sciences

Medical device maker Medtronic Plc said on Wednesday Chief Executive Officer Omar Ishrak will retire in April 2020 and will be succeeded by senior executive Geoff Martha.

Ishrak, who will turn 65 next year, spearheaded Medtronic’s nearly $43 billion deal for rival Covidien in 2015, the largest acquisition in the medical technology industry that helped the company redomicile to Ireland, lowering its overall tax burden.

Martha, who will become CEO on April 27 next year, led the integration of Covidien and Medtronic and currently is executive vice president of restorative therapies group (RTG), a unit that sells devices such as spinal implants and robotic surgery systems.

“Investors will be hugely supportive of Geoff taking on the CEO role,” Evercore ISI analyst Vijay Kumar said, noting that it was the right time for the transition.

Martha, who has been with Medtronic since 2011, turned the RTG unit around mainly through the acquisition of Israeli robotics company Mazor Robotics in 2016, which gave Medtronic access to robotic spine surgery system, Mazor X.

The unit generated revenue of more than $8 billion in fiscal 2019, but is Medtronic’s third biggest unit. As a result, Martha’s appointment may be a surprise to some investors, Wells Fargo analyst Larry Biegelsen said, although he does not expect a shift in strategy under Martha in the near term.

From November, Martha will assume a newly created role as Medtronic’s president and join the company’s board. Ishrak will continue as board chairman and will take up a new role as executive chairman of Medtronic after he retires.

Brett Wall, who joined Medtronic from Covidien, will succeed Martha as the executive vice president of the RTG unit.

By Manas Mishra and Manojna Maddipatla

Source: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach